APA (7th ed.) Citation

Li, B., Fan, K., Zhang, T., Wu, Z., Zeng, S., Zhao, M., . . . Liang, X. (2024). Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial. Ophthalmology & Therapy, 13(1), 353. https://doi.org/10.1007/s40123-023-00836-4

Chicago Style (17th ed.) Citation

Li, Bing, et al. "Efficacy and Safety of Biosimilar QL1207 Vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial." Ophthalmology & Therapy 13, no. 1 (2024): 353. https://doi.org/10.1007/s40123-023-00836-4.

MLA (9th ed.) Citation

Li, Bing, et al. "Efficacy and Safety of Biosimilar QL1207 Vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial." Ophthalmology & Therapy, vol. 13, no. 1, 2024, p. 353, https://doi.org/10.1007/s40123-023-00836-4.